4LN2 Stock Overview A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Capricor Therapeutics, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Capricor Therapeutics Historical stock prices Current Share Price US$12.20 52 Week High US$20.45 52 Week Low US$3.27 Beta 4.03 1 Month Change -26.33% 3 Month Change 177.27% 1 Year Change 208.86% 3 Year Change 329.58% 5 Year Change 1,050.94% Change since IPO 22.00%
Recent News & Updates
Third quarter 2024 earnings released: US$0.38 loss per share (vs US$0.25 loss in 3Q 2023) Nov 14
Capricor Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 05
New major risk - Shareholder dilution Oct 20 Capricor Therapeutics, Inc. Intends to File A Biologics License Application Capricor Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.004 million.
Capricor Therapeutics Announces Positive Long-Term Data from Hope-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress Oct 12 See more updates
Third quarter 2024 earnings released: US$0.38 loss per share (vs US$0.25 loss in 3Q 2023) Nov 14
Capricor Therapeutics, Inc. to Report Q3, 2024 Results on Nov 13, 2024 Nov 05
New major risk - Shareholder dilution Oct 20 Capricor Therapeutics, Inc. Intends to File A Biologics License Application Capricor Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $75.004 million.
Capricor Therapeutics Announces Positive Long-Term Data from Hope-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress Oct 12
Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy Oct 09 Sep 24
New minor risk - Profitability Sep 24 Capricor Therapeutics, Inc. announced that it has received $14.999998 million in funding from Nippon Shinyaku Co., Ltd. Sep 18
Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.29 loss in 2Q 2023) Aug 08
Capricor Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Jul 31
New major risk - Financial position Jul 01
Capricor Therapeutics, Inc. Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy Jun 29
Capricor Therapeutics, Inc. Announces for the Treatment of Duchenne Muscular Dystrophy Jun 25
New minor risk - Profitability Jun 07
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from Hope-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Jun 05
Forecast breakeven date pushed back to 2026 May 17
First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.31 loss in 1Q 2023) May 14
Capricor Therapeutics, Inc. to Present Exosome Platform Updates At the American Society of Gene and Cell Therapy 27Th Annual Meeting May 10
Capricor Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024 May 08
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy Apr 24
Capricor Therapeutics, Inc., Annual General Meeting, May 14, 2024 Apr 02
New major risk - Share price stability Mar 29
Capricor Therapeutics, Inc. to Present Positive 24-Month Results from its HOPE-2 Open-Label Extension Study at 2024 Muscular Dystrophy Association Clinical & Scientific Conference Mar 07
Forecast breakeven date pushed back to 2026 Mar 05
Full year 2023 earnings released: US$0.83 loss per share (vs US$1.18 loss in FY 2022) Mar 03
Capricor Therapeutics, Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2 Jan 24
Capricor Therapeutics Announces Continuation of Phase 3 Hope-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis Dec 12
New major risk - Financial position Nov 19
Capricor Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023 Nov 08
New minor risk - Market cap size Oct 03
Capricor Therapeutics Announces Positive Type-B Meeting with the FDA to Discuss Pathway to BLA for CAP-1002 in Duchenne Muscular Dystrophy Oct 01
Capricor Therapeutics, Inc. Appoints Michael Kelliher to Its Board of Directors Sep 07
New major risk - Share price stability Aug 25
Insufficient new directors Aug 25
Forecast breakeven date moved forward to 2024 Aug 08
Capricor Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Aug 03
Insufficient new directors Aug 01 Capricor Therapeutics Announces the Appointment of Philip J. Gotwals to Its Board of Directors
Capricor Therapeutics, Inc Announces Board Changes Jul 14
Capricor Therapeutics Announces Positive 24-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Jul 01
Capricor Therapeutics Announces Follow-up Type-B Clinical Meeting with the FDA for CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Jun 08
Forecast breakeven date moved forward to 2024 May 14
Capricor Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Full year 2022 earnings released: US$1.18 loss per share (vs US$0.87 loss in FY 2021) Mar 18
Forecast breakeven date moved forward to 2024 Mar 18
Capricor Therapeutics, Inc. Announces Positive 18-Month Results from Ongoing HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy Patients Jan 26
Forecast to breakeven in 2025 Dec 31
Insufficient new directors Nov 17
Third quarter 2022 earnings released: US$0.26 loss per share (vs US$0.17 loss in 3Q 2021) Nov 12
Capricor Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Capricor Therapeutics, Inc. to Report Q2, 2022 Results on Aug 10, 2022 Aug 04
Capricor Therapeutics, Inc. Announces First Patient Dose in Pivotal Phase 3 Study of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy Jul 20
Independent Director recently sold €74k worth of stock Jul 01
Capricor Therapeutics, Inc. Announces Statistically Significant Clinical Benefits in Skeletal Muscle Function in Non-Ambulant Duchenne Muscular Dystrophy Patients Treated with Cap-1002 in Hope-2 Open Label Extension Study Jun 28
Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer May 26
First quarter 2022 earnings released: US$0.32 loss per share (vs US$0.23 loss in 1Q 2021) May 11
Capricor Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022 May 04
Insufficient new directors Apr 29
Capricor Therapeutics, Inc., Annual General Meeting, Jun 03, 2022 Apr 14
Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory Inspire Trial in Severe Hospitalized Covid-19 Patients Mar 29
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 12
Capricor Therapeutics, Inc. to Report Q4, 2021 Results on Mar 10, 2022 Mar 06
Capricor Therapeutics, Inc. Announces Key Updates on Its Vaccine and Therapeutic Programs for COVID-19 Dec 15
Third quarter 2021 earnings released: US$0.17 loss per share (vs US$0.20 loss in 3Q 2020) Nov 11
Capricor Therapeutics Announces Positive Final Data from Its Phase 2 Hope-2 Trial in Patients with Duchenne Muscular Dystrophy Treated with Cap-1002 Sep 25
Forecast to breakeven in 2023 Sep 23
Capricor Therapeutics, Inc. to Present Final Data from Hope-2 Trial with Cap-1002 in Duchenne Muscular Dystrophy At World Muscle Society 2021 Sep 03
Second quarter 2021 earnings released: US$0.21 loss per share (vs US$0.23 loss in 2Q 2020) Aug 14
Capricor Therapeutics Announces to Present Findings from HOPE-2 Open-Label Extension Study at Parent Project Muscular Dystrophy (PPMD) 2021 Virtual Annual Conference Jun 18
First quarter 2021 earnings released: US$0.23 loss per share (vs US$0.30 loss in 1Q 2020) May 15
Capricor Therapeutics Provides Corporate Update May 14
Full year 2020 earnings released: US$0.88 loss per share (vs US$2.06 loss in FY 2019) Mar 13
Revenue beats expectations Mar 13
Capricor Therapeutics Announces New Advances in Exosome-Mediated Mrna Delivery Platform Mar 11
Capricor Therapeutics, Inc. to Report Q4, 2020 Results on Mar 11, 2021 Mar 05
New 90-day high: €6.45 Feb 11
Capricor Therapeutics, Inc. Announces Development of Serology Test to Confirm Activity of SARS-CoV-2 Vaccines Feb 02
Capricor Collaborates with Lonza for the Development of Cap-1002, Its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications Jan 13
New 90-day low: €2.92 Jan 07
Capricor Therapeutics Announces DSMB Recommendation to Continue Phase II INSPIRE Trial for Severe COVID-19 Patients Dec 30
New 90-day low: €3.22 Dec 23
Capricor Therapeutics, Inc. Commences Dosing Patients in Phase 2 Trial of CAP-1002 in Patients with Severe COVID-19 Nov 26
Third quarter 2020 earnings released: US$0.20 loss per share Nov 13
Capricor Therapeutics Announces Positive Preclinical Data for Multivalent Exosome-mRNA Vaccine For COVID-19 Nov 10
Capricor Therapeutics, Inc. to Report Q3, 2020 Results on Nov 12, 2020 Nov 06
New 90-day low: €3.66 Oct 21 Shareholder Returns 4LN2 DE Biotechs DE Market 7D -7.7% -2.9% -2.6% 1Y 208.9% -14.7% 6.9%
See full shareholder returns
Return vs Market: 4LN2 exceeded the German Market which returned 6.9% over the past year.
Price Volatility Is 4LN2's price volatile compared to industry and market? 4LN2 volatility 4LN2 Average Weekly Movement 28.5% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.2% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 4LN2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4LN2's weekly volatility has increased from 17% to 28% over the past year.
About the Company Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Show more Capricor Therapeutics, Inc. Fundamentals Summary How do Capricor Therapeutics's earnings and revenue compare to its market cap? 4LN2 fundamental statistics Market cap €569.57m Earnings (TTM ) -€32.69m Revenue (TTM ) €22.26m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4LN2 income statement (TTM ) Revenue US$23.23m Cost of Revenue US$45.35m Gross Profit -US$22.13m Other Expenses US$11.99m Earnings -US$34.11m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.75 Gross Margin -95.25% Net Profit Margin -146.86% Debt/Equity Ratio 0%
How did 4LN2 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 12:32 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Capricor Therapeutics, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Kristen Kluska Cantor Fitzgerald & Co. Reni Benjamin H.C. Wainwright & Co. Joseph Pantginis H.C. Wainwright & Co.
Show 7 more analysts 
